Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired.
The deal has already been approved by the boards of directors from both companies.
Founded in 2009, Shockwave focuses on intravascular lithotripsy technology that uses sonic pressure waves to crack calcium lesions in arteries and restore blood flow. It’s similar to a technique used to break up kidney stones. The soundwave emitters are placed inside angioplasty catheters to reach the calcified areas of the artery.
Shockwave’s technology is used to treat coronary artery and peripheral artery disease.
The company’s revenue jumped 49% last year to $730 million.
Family appeals ruling that threw out lawsuit over 2017 BIA shooting death in North Dakota
Across China: A Glimpse into Thriving Ice and Snow Industry in Xinjiang
Young Lodgers Bring Joy to Elderly Nursing Home Residents' Lives
People Across China Celebrate Chinese Lunar New Year
Google workers fired over Israeli contract protests file complaint with labor board
Street Dance in China — from Niche to Pop Culture Phenomenon
Children Pick Strawberries at Hanging Strawberry Farm in E China's Zhejiang
Children Visit Beijing Auto Museum During Winter Vacation
Mom shopping in Target stunned by small print on Clorox wipes
Youthful Spirits Revitalize Life of Aged Students
G7 nations commit to phasing out coal by 2035 but give Japan some flexibility
Rural Tourism Sees Robust Growth